A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Dermira
- 22 Feb 2018 According to a Dermira media release, topline results from this trial are expected in the first half of 2019.
- 31 Jan 2018 According to a Dermira media release, status changed from planning to recruiting.
- 11 Aug 2017 New trial record